Diagnostics, Journal Year: 2024, Volume and Issue: 15(1), P. 68 - 68

Published: Dec. 30, 2024

Background: Chronic liver disease (CLD) presents a significant global health burden, demanding effective tools for diagnosis and monitoring. Traditionally, biopsy has been the gold standard evaluating fibrosis other chronic conditions. However, biopsy’s invasiveness, associated risks, sampling variability indicate need reliable, noninvasive alternatives. This review examines utility of tests (NITs) in assessing severity, progression, therapeutic response patients with CLD. Result: Key modalities discussed include serum biomarker panels (e.g., FIB-4, APRI, ELF), imaging techniques like transient elastography, magnetic resonance each offering unique benefits staging. Emerging biomarkers such as extracellular vesicles circulating microRNAs show promise early detection personalized Comparative studies that while no single NIT matches precision, combinations these improve diagnostic accuracy patient outcomes by reducing unnecessary biopsies. Moreover, NITs are instrumental monitoring dynamic changes health, allowing more responsive patient-centered care. Conclusions: Challenges remain, including standardization across tests, cost considerations, larger, diverse population to validate findings. Despite limitations, increasingly integrated into clinical practice, fostering paradigm shift toward noninvasive, accessible management. Continued advancements essential improved will likely shape future care

Language: Английский